Landscape of Clinical Trials in Cancer Cachexia: Assessment of Trends From 1995-2024

Ana Regina Cabrera[1*], Kaitlyn Parker[1*], Deena B. Snoke[2], Bart Hammig[3], Nicholas P. Greene[1].

[1]Cachexia Research Laboratory, Exercise Science Research Center, Department of Health, Human Performance and Recreation, University of Arkansas, Fayetteville AR, United States
[2]Department of Medicine, University of Vermont College of Medicine, Burlington VT, United States
[3]Public Health Program, Department of Health, Human Performance and Recreation, University of Arkansas, Fayetteville AR, United States

Corresponding Author:

Nicholas P. Greene
HPER 321E
University of Arkansas
155 Stadium Dr.
Fayetteville, AR 72701
Phone number: 479-575-6638
Fax: 479-575-2853
npgreene@uark.edu

* These authors contributed equally to this work

Abstract

Background: Cancer cachexia, a multifactorial syndrome characterized by unintentional weight loss, is a frequent complication of cancer that impacts patients' quality of life and survival. **Methods:** In this retrospective review, we evaluated the landscape of clinical trials registered on ClinicalTrials.gov for the consideration of potential factors contributing to biological human heterogeneity in their design and analyses. **Results:** Among clinical trials registered from 1995-2024, we observed increased inclusion of female participants, but lack of reporting of sex as a biological variable. The majority (~93%) of participants were of Caucasian descent. There was a substantial divergence in the diagnostic criteria and a wide range of tools employed to measure cancer cachexia. Lastly, few studies considered cancer type and stage as clinical variables. **Conclusion:** Overall, a substantial gap remains in our knowledge of cancer cachexia in non-white individuals and in females. Ultimately, these underreported data across cancer cachexia clinical trials complicate the comparison and interpretation of clinical trials results, both in the broader human population and in specific cancer types. The current evolution of knowledge and new methodologies used for cancer cachexia assessment reinforce the need for a constant revision of the consensus definition and diagnosis criteria to align with current advances in our understanding of human heterogeneity in cancer cachexia.

Keywords:

Biological sex, Consensus, Quality of Life, Retrospective Studies, Weight loss, Neoplasms

Background

Cancer is a critical global public health concern, with 9.7 million cancer-related deaths recorded worldwide in 2022 (1). Among all cancer types, lung, gastrointestinal, and pancreatic cancers are together estimated to comprise 38% of all cancer-related deaths in the United States (2). Cancer cachexia (CC), defined by Fearon et al. in 2011 as a multifactorial syndrome characterized by unintentional ongoing muscle loss which may occur with or without fat loss that is irreversible by conventional nutritional support (3), is a frequent complication of cancer which occurs at high rates in the cancer types mentioned above. CC is commonly clinically identified by decreased body weight or changes in body composition, which inevitably leads to impaired physical function. Because reliable body composition data are challenging, expensive, and impossible to retrospectively collect in a clinical setting, diagnostic criteria for CC have focused on body weight loss, with patients losing more than 5% of body weight or underweight patients (BMI<20 kg/m^2) losing more than 2% of body weight in the past six months meeting criteria for CC (3). Clinical presentation of CC is a valuable metric to oncologists, as patients experiencing CC have increased fatigue (4), muscle weakness (5), treatment-related toxicities (6, 7), and decreased survival (5). Additionally, the frequency of CC is clinically significant, as its incidence increases in late-stage cancers (8), can be experienced in up to 80% of patients depending on cancer type (3, 9, 10) and is the main cause of mortality in ~20-40% of cancer-related deaths (11).

Despite its prevalence and impact, efforts to develop preventative and therapeutic treatments for CC, including dietary supplements, exercise, and pharmaceutical drugs have had minimal success to date. The scientific community has acknowledged that these challenges may be due to the widespread use of preclinical models that may not faithfully recapitulate the human

condition (12, 13), especially when extrapolated across cancers and other biological variables. Additionally, characteristics of CC can vary significantly depending on cancer type, tumor location, metabolism, mutational identity, and stage (7), which, due to the necessity of repeatability in disease models, is often not well reflected in preclinical studies. This is further complicated by factors intrinsic to human heterogeneity, which leads to significant variation in CC symptoms among individuals. One such factor that has gained traction in recent years is the effect of biological sex on CC characteristics (14). Clinically, males appear to exhibit well-described signs of CC earlier during cancer progression and undergo more significant declines in muscle mass in comparison to females (14). The observation that males adhere to this more 'typical' pattern of CC is partially due to the fact that historically, the majority of preclinical studies have utilized male mice or do not address biological sex as an experimental variable, and thus our understanding of the manifestation of CC in females is limited (15). Additionally, it is currently not feasible to capture the complexities of human genetic, environmental, and social factors such as race and ethnicity in preclinical models. However, recent patient data suggest that race and ethnicity demographics do impact disease outcomes such as CC incidence and mortality (16-19), underscoring the importance of studying diverse populations in clinical studies and trials to understand the genetic and environmental factors, including health disparities, contributing to disease outcomes. Additionally, the breadth of diagnostic measures reported across studies in human patients may contribute to inconsistencies in the literature that prevent pooled or comparative analyses across trials. The aim of the present review was to conduct a comprehensive assessment of CC clinical trials (CTx) between 1995-2024 and evaluate how these studies consider potential factors, such as demographic characteristics, intervention type, cancer type, and reported measures, contributing to heterogeneity of patient populations in their

design, analyses, and interpretation. In doing so, we identify effective measures used by these studies and areas where alternative methods and considerations should be employed to address gaps in knowledge. Ultimately, the goal of this assessment is to aid in the advancement of future research initiatives by the design of more comprehensive and effective CTx in CC.

Methods

This is a retrospective systematic review to analyze CTx investigating CC registered on ClinicalTrials.gov.

Eligibility Criteria

Inclusion criteria were interventional and observational CTx investigating CC in child and adult subjects, both male and female, published on ClinicalTrials.gov. Trials were included if CC, cancer-induced sarcopenia, or cancer-induced muscle wasting were the primary reason for the study. Completed trials, active trials, and terminated trials were included. Exclusion criteria included trials that were unrelated to CC and trials measuring non-cancer induced cachexia. No trials were excluded based on country, region, total enrollment, trial start or completion date.

Information Sources

The primary data source for this research was ClinicalTrials.gov, a comprehensive database providing information about clinical research studies conducted throughout the world. For trials listed without study results, PubMed was utilized to search for published manuscripts including results associated with them.

Search Strategy

This search was conducted through ClinicalTrials.gov from December 2023 to August 2024, regardless of country and focusing on the condition/disease filter in the search generator. Terms related to CC, including “cancer cachexia”, “cachexia”, “sarcopenia”, and “muscle wasting” were searched one at a time. If “cachexia”, “sarcopenia”, or “muscle wasting” was the primary search term in the condition filter, “cancer” was added as a secondary search term in the other terms filter. No terms were added to the intervention/treatment filter or location filter. All boxes under study status were selected. The “all” option was selected under the sex filter. All age ranges were selected under the age filter. “Early Phase 1”, “Phase 1”, “Phase 2”, “Phase 3”, and “Phase 4” were selected under the study phase filter. Both “Interventional” and “Observational” were selected under the study type filter. “With results” and “Without results” were selected under the study results filter. No options were selected under the study documents, funder type, and date range filters. No additional information was input into the “More ways to search” section. When utilizing PubMed, the CTx official name followed by the study director’s name were searched.

Data Collection Process

Data from eligible CTx were extracted from ClinicalTrials.gov. Official study title, ClinicalTrials.gov ID (NCT number), sponsor, study director, study start date, actual or estimated study completion date, study status, study type, enrollment, intervention(s), participant demographics, primary and secondary outcome measures, the type(s) of cancer included, CC definition used, and any listed publications were collected as reported on ClinicalTrials.gov. The same data were extracted from trials that lacked results or other data on ClinicalTrials.gov but were found in published manuscripts on PubMed. Published manuscripts were matched to CTx

on ClinicalTrials.gov by NCT number. Principal investigators and participation enrollment were used as secondary confirmation to ensure the manuscript discussed the clinical trial of interest.

Data Synthesis

The extracted data was grouped based on a variety of measures, including start and completion date of the trial, the treatment/intervention, type of cancer(s), CC definition used, and outcome measures. The list of CTx included is in **Supplemental File 1**.

Figures and Tables

Figures were made with Biorender or R (v4.4.1). Tables and database were managed with Microsoft365 Word and Excel.

Results

The searches conducted in ClinicalTrials.gov generated 209 trials using “cancer cachexia”; “cachexia” + “cancer” generated 226 results; “sarcopenia” + “cancer” generated 126 results; and “muscle wasting” + cancer” generated 143 results. After removing duplicates, 491 individual trials remained. After title and abstract screening, 300 trials did not meet the inclusion criteria. Therefore, the remaining 191 trials were included in this analysis. Of these, 106 trials had the status of complete, 10 of which had results published on ClinicalTrials.gov and 42 had published results in manuscripts available from PubMed, resulting in 52 completed trials with results. The remaining 54 completed trials did not have results identified on either ClinicalTrials.gov or PubMed. In addition, 62 trials were active, and 23 were terminated or withdrawn before completion at the conclusion of the search (**Supplemental File 2**). The reasons

for termination are listed in **Supplemental File 3**, with none of the trials being terminated by safety boards. Moreover, most of the CTx (116, 60.7%) did not have a phase stated, 15 (7.9%) were in phase 1, 31 (16.2%) were in phase 2, 20 (10.5%) were in phase 3, 2 (1.0%) in phase 4, and 7 (3.7%) were in between two different phases (**Supplemental File 4**).

Clinical Trial Demographics

We generated an overview of demographic composition of patients and how it was reported based on the 52 CTx with published findings. A summary of the reported demographics for age, biological sex, race, and ethnicity is compiled in **Figure 1a**.

From the 52 CTx with results reported, 100% reported the ages of participants; of those, 50 trials (96.2%) reported the mean or median age of patients, ranging from 11 to 75 years old. From these 52 CTx, eight trials (15.4%) reported patient numbers by age categories (<18, 18-64, and >64). A total of 49 trials (94.2%) reported biological sex of participants and only one from the CC-CTx completed with results (1.9%) reported clinical outcomes by biological sex (NCT02148159). Among all trials with sex reporting, there were 3,103 females (40.4%) and 4,573 males (59.6%). In addition, we calculated the percentage of female and male participants within each study and the mean percentage had a similar distribution with 43.5% females and 56.5% males. However, we observed different trends across years. We noted an average of 38.7% females and 61.3% males in CTx with results reported from 2004 to 2014, while the average reported in CTx from 2015 to 2023 showed average distributions closed to equality with 48.8% of female and 51.2% of male participants (**Figure 1b**). In addition, 17 trials (32.7%) reported race of participants. Of these trials, all (100%) reported the participation of White patients. Fourteen trials (82.4%) reported the participation of Black or African American

patients, six trials (35.3%) included Asian patients, two (11.8%) reported participation of Native Hawaiian/Pacific Islander individuals, one (5.9%) included Pardo patients, 9 (52.9%) included an unknown or mixed category, and no trials included American Indian/Alaska Native patients. Among all trials reporting race, there were 2,135 (92.6%) White patients, 77 (3.3%) Black or African American patients, 21 (0.9%) Pardo, 12 (0.5%) Asian patients, 2 (0.1%) Native Hawaiian/Pacific Islander patients, and 0 Native American/Alaskan Native patients or other races reported (**Figure 1c**). No trials reported clinical outcomes by race in a subgroup analysis. In addition to race, only five trials (9.6%) reported the ethnicity of participants. Among trials reporting ethnicity, 100% reported Hispanic/Latino patients making a 0.7% of the total population included in the CTx completed with results. Besides Hispanic/Latino participants, no other specific ethnicities were reported. No trials reported clinical outcomes by ethnicity in a subgroup analysis. Overall, CTx include both sexes but fail to report sex as a biological variable. Additionally, there is a significant knowledge gap in the study of CC among races and ethnicities other than the White population.

Cancer Cachexia Definition and Classification

Despite the existence of a consensus definition of cachexia, the application of the diagnostic criteria remains only partially implemented in clinical practice. Therefore, we decided to classify the CTx according to the diagnostic criteria used to define CC. Our analysis demonstrated that of all trials included in this study (n = 191), 61.8% defined how they classified CC (**Figure 2a**). A significant portion of the studies (64, representing 33.5%) used the Fearon et al. consensus definition (3), stating a degree of loss and time frame for its occurrence. Studies that used weight loss greater than 5% in the past six months as their criteria, or weight loss

greater than 2% in individuals already showing depletion with body mass index (BMI) <20 kg/m^2 or skeletal muscle mass loss were classified as 'Fearon'. Studies that defined CC in a different way (54, 28.3%), were classified as 'Other'. Other criteria included different consensus definitions such as the Asian Working Group for Sarcopenia (AWGS) (20) European Society for Clinical Nutrition and Metabolism (ESPEN) (21), or European Working Group on Sarcopenia in Older People (EWGSOP2) (22). Other definitions included variations in time statements (1-12 months) or no statement regarding time frame, different body weight loss degrees (from 2-20%) or no statement about loss degree, other BMI ranges, or definitions by caloric intake or anorexia. Some other research groups utilized scores and tools such as the Edmonton Symptom Assessment Score (ESAS), Malnutrition Universal Screening Tool (MUST), Eastern Cooperative Oncology Group (ECOG), Karnofsky Performance Index, among others. Lastly, 74 (38.2%) CTx did not specify how they accounted for CC in their study. The distribution of the CC definitions used across years (1995-2024) is represented in **Figure 2b**. Although the Fearon consensus definition was published in 2011, the involuntary weight loss of ≥ 5% within the previous six months has been employed as a CTx criterion in studies initiated as early as 2005 (NCT00219817, NCT00267358, NCT00899158) (23). It is noteworthy that despite having several criteria and a consensus definition to diagnose CC, numerous studies fail to describe the diagnostic criteria used.

The current status of CTx stratified by their CC definition criteria and terms used for trial classification are summarized in **Supplemental Files 5 and 6**. Of 52 CTx completed with results, 29 (55.8%) specified the use of the Fearon et al. consensus definition. Fourteen trials (26.9%) used definitions other than the Fearon et al., with six of those trials beginning after the consensus definition was established in 2011. Nine trials (17.3%) did not specify the criteria used

for how they defined CC. Moreover, five trials (9.6%) were classified under “sarcopenia”, nine trials (17.3%) were classified under “weight loss”, four trials (7.7%) were classified under “muscle wasting” or “muscle loss”, and four trials (7.7%) were classified under “malnutrition” or “anorexia”. Within the completed trials without results**,** nine trials (16.6%) specified the use of the 2011 Fearon et al. consensus definition. Nineteen trials (35.2%) used definitions other than the Fearon et al. definition, with 11 of those trials beginning after the consensus definition was established in 2011. Twenty-six trials (48.2%) did not specify how they defined CC. From these trials without results, six trials (11.1%) were classified under “sarcopenia”, ten trials (18.5%) were classified under “weight loss”, six trials (11.1%) were classified under “muscle wasting” or “muscle loss”, and three trials (5.5%) were classified under “malnutrition” or “anorexia”. For the CTx that were still active at the completion of the search, 24 (38.7%) specified the use of Fearon definition and eight trials (12.9%) used other definitions. Thirty (48.4%) did not specify how they defined CC for their study. Among these active studies, 16 (25.8%) have been classified under “sarcopenia”, one trial (1.6%) under “weight loss”, nine trials (14.5%) under “muscle wasting” or “muscle loss”, and one trial (1.6%) classified under “malnutrition” or “anorexia”. From the withdrawn trials, two (8.7%) used Fearon definition, 13 (56.5%) used other definitions, and eight (34.8%) did not specify their criteria to classify CC. Three trials (13.0%) were classified under “weight loss”, one trial (4.4%) was classified under “muscle wasting” or “muscle loss”, and one trial (4.4%) was classified under “malnutrition” or “anorexia”.

Sample Size, Cancer Types, and Clinical Approaches Across Clinical Trials

We characterized study participants among CTx to determine the number of registered participants and the cancer type and stage studied in each trial. Across all trials (n = 191), 72

(37.7%) enrolled between 1-50 patients, 49 trials (25.7%) enrolled between 51-100 patients, 51 (26.7%) enrolled between 101-500 patients, six (3.1%) enrolled between 501-1000 patients, four (2.1%) enrolled more than 1000 patients, and nine trials (4.7%) did not specify the total enrollment, most of which were from withdrawn trials. The distribution of patients' enrollment per clinical trial status is shown in **Supplemental Files 7A and 7B**.

Analysis of the CTx by cancer type show that 50.3% of trials studied CC in a specific type of cancer, 8.9% studied two cancer types, 5.2% studied three cancer types, 11.5% studied four or greater cancer types, and 24.1% did not state the cancer type considered for their study (**Figure 3a**). Among these CTx, CC has been studied more predominantly in lung and gastrointestinal related cancers (pancreatic, gastric, colorectal), either individually or in combination with other cancer types. In addition, between 10-35% of the trials did not report a concurrent anti-cancer treatment despite that it is standard of care (data not shown), and the majority did not report the cancer stages represented in the study (146, representing 76.4%). Of those trials reporting patient cancer stage (n=45), 53.3% investigated CC in advanced stage cancers (stage III-IV), while other stages were reported between 2-15% (**Figure 3b**). **Supplemental File 8** details the stratification of cancer type and stage per CTx status.

CTx studying the effects of CC employed either an observational (26.7%) or an interventional (73.3%) study design. The most common intervention was pharmaceutical (33.5%, "drug" on the Figure), followed by dietary supplements (14.7%), exercise (7.9%), and different multimodal approaches (9.4%). Multimodal interventions included different combinations of dietary supplements, nutrition, exercise, drugs, counseling, and psychological support. The interventions used by CTx status are detailed in **Supplemental File 9** and a list of the drugs and

dietary supplements utilized as intervention are detailed in **Supplemental File 10**. The frequency of intervention types over time among CC-CTx can be visualized in **Figure 3c**. These trends indicate that drug treatment interventions remain a popular approach over time. Additionally, a noticeable increase in the use of exercise and dietary interventions is observed following the Fearon consensus definition in 2011.

Outcome Measures and Tools Used

To understand how CTx assessed CC, we summarized the evaluated parameters and the tools that have been used to measure them. First, we looked for body weight, a parameter considered in most CC definitions, and only 42.4% of studies included body weight as an outcome measured, from these, only 20% were prior to Fearon's CC definition (**Figure 4a**). A total of 62.3% of studies report the use of body composition across all trials (with only 18.5% of them prior Fearon's CC definition in 2011), with 25.7% reporting muscle mass, 23.6% reporting lean body mass, and 11.0% reporting fat mass, among others (**Figure 4b**). To assess body composition, computed tomography (CT) was the most used technique (18.3%), followed by bioelectrical impedance analysis (BIA, representing 17.3%) and dual energy x-ray absorptiometry (DXA, 12.6%). Physical function was an outcome measure in 50.3% of CTx, including measures of muscle function or muscle strength (29.3%), physical activity levels (13.6%), and fatigue (7.3%) (**Figure 4c**). To assess physical function, 26.2% of the trials used hand grip strength and 13.1% used a 6- or 10-minute walk test, with other methodologies used less frequently. Quality of life (QoL) was specified by 37.2% of the trials (**Figure 4d**), and it was mostly evaluated by the ECOG Performance Status Scale (33.0%), the European Organization for the Research and Treatment of Cancer QoL Questionnaire (EORTC QLQ, 20.9%), and by the

Functional Assessment of Anorexia/Cachexia Treatment (FAACT, 13.6%), among others. Nutrition and appetite were mentioned by 30.4% of the CTx and dietary recall or food diaries were the methodologies most used (9.4%) (**Figure 4e**). Molecular measures were mentioned in 45.5% of the studies, with ~45% of them stated in CTx studying CC in the last 5 years (**Figure 4f**). Of those studies reporting molecular measures, most studies assessed blood samples (44.5%) while some reported use of muscle biopsies (11.0%), the specific targets measured are listed in **Supplemental File 11**. Lastly, 21.5% of CTx specified the measure of safety and tolerability, and 19.4% reported survival (**Figures 4g and 4h**). Outcomes measured and other tools that have been used to a lesser extent are detailed by clinical trial status on the **Supplemental Files 12 and 13**.

Discussion

While significant progress has been made in the understanding of the pathogenesis of CC and in establishing potential therapeutic interventions, CC significantly decreases quality of life and remains a main cause of death for many cancer patients, while successful treatment strategies have not yet been identified. Through evaluation of CC CTx, we assessed aspects of human heterogeneity that are not well-addressed in carefully controlled animal studies and assess changes in study approaches and improvements in these metrics over time. Our findings suggest a large knowledge gap in how CC differs across patient populations and how this impacts health outcomes. Expanding CTx to improve representation across patient populations may improve progress toward effective treatments for CC.

Reporting of Demographic Factors

It was not until 1993 that in the United States (U.S.), the National Institutes of Health (NIH) Revitalization Act was passed requiring recruitment and inclusion of women and racial and ethnic minorities in clinical research studies. In 2011, almost 20 years afterwards, the Institute of Medicine of the National Academies suggested reporting results by biological sex be required for the publication of CTx results, as lack of reporting had significantly slowed the advancement of women's health (24, 25). Recognizing sex-based biological differences is essential for understanding mechanistic and pathophysiological divergence during the onset and progression of pre-clinical studies of CC (14, 15). Therefore, the acknowledgment of women's inclusion in CTx alone is insufficient. In 2015, the NIH announced the requirement for sex to be considered as a biological variable in NIH-supported preclinical and clinical studies. Herein, we identified that across all CC-CTx completed with results, 5.8% did not report sex at all, while 59.6% of the total patient population was male. This is consistent with recent findings that across studies assessing longitudinal body composition in patients with lung cancer, 65% of all study participants were male (26). Additionally, in the present review we find that between 2015-2024, the percentage of enrolled females increased to 48.4% of patients, reflecting increased equality of enrollment of males and females in CTx over time suggesting enhanced equity. At present, significant advancements have been made in understanding the pathogenesis of CC, but still very little is known about how biological sex as a variable affects patient outcomes with CC. Despite improved equality of enrollment, trends are yet to come to fruition for the consideration of biological sex as a variable in data analyses, as in twenty-nine years we only identify one CTx reporting sex subgroup analysis. Our findings highlight that despite many positive changes in the conduct of clinical studies, inequalities persist, likely contributing to suboptimal progress.

Understanding sex as a biological variable in clinical CC will ultimately increase the ability to accurately model the complications of the human condition, and in turn, develop effective treatments improving health outcomes for both males and females with CC.

Approximately one-third of CTx completed with results reported race, while less than one-tenth reported ethnicity. Of CTx reporting race and ethnicity, there was a lack of racial and ethnic diversity among enrolled patients. Among CTx reporting race, 92.6% of all patients were White. In CTx reporting ethnicity, 100% focus solely on Hispanic/Latino individuals, neglecting other ethnicities. This homogeneity fails to reflect the true representation of the general population and highlights the scarcity of information about CC in non-white individuals, severely limiting the understanding of how race and ethnicity affect CC. Importantly, a recent study reports that Black patients were more frequently excluded from clinical studies due to comorbidities, rendering them ineligible for participation (27). Based on our findings, these eligibility criteria may exacerbate disparaged enrollment that expands beyond only PDAC patient populations and should be considered in future clinical studies. Through 2024, recent calls for applications from the National Cancer Institutes in the U.S. highlighted the dire need to understand cancer burden across population groups. Although contributions to this area of research are currently minimal, there have been significant recent findings that provide evidence for possible genetic, environmental, and socioeconomic differences across race and ethnicity warranting further studies. For instance, across all stages of lung cancer, Black race strongly increased the odds of experiencing pretreatment weight loss (17) and in patients with advanced lung cancer, Black race and Hispanic ethnicity presented with greater risk of developing CC (16). The Florida Pancreas Collaborative has made great strides in understanding racial and ethnic differences in pancreatic CC, reporting greater frequency of cachexia markers in Blacks

with concurrent higher cancer incidence and mortality and shorter survival time (18, 19). Additionally, Hispanic/Latino patients experienced increased survival time compared to non-Hispanic White individuals and Black individuals (19). This suggests underlying genetic, environmental, socioeconomic, and/or yet unknown factors predisposing patients to increased risk of developing CC, which may differ beyond cancer type. Despite these observations, no CTx reported clinical outcomes by race or ethnicity in a subgroup analysis. As with biological sex, race and ethnicity should be included in subgroup analyses for clinical outcomes across CC studies; however, studies must be statistically powered for these analyses and thus recruitment of a racially and ethnically diverse study population is critical.

Inconsistent Cancer Cachexia Definitions and Varied Diagnostic Criteria

Despite that a consensus CC definition was published in 2011 (3), we found considerable heterogeneity in the definition and diagnostic criteria used across CTx, with only 33.5% of studies using the consensus definition criteria to classify CC. Additionally, there have not been improvements in these metrics over time. Significant variations in classification persist, with a significant portion (38.2%) of CTx not reporting the details of their classification methods, which presents an enormous challenge in interpreting and comparing results across CTx. Additionally, a significant portion of studies use description of symptoms to define CC, including sarcopenia, muscle wasting/loss, anorexia, and malnutrition. The inconsistency in the terminology and diagnostic guidelines may lead to misdiagnoses, absent medical records, and inaccurate reports of cachexia incidence, likely concealing the visibility of the impact of CC on public health. Altogether, these gaps reflect a systemic oversight of clinically important characteristics of the syndrome. The lack of standardization demands action to unify criteria and

reporting practices to enable meaningful data integration and cross-study comparisons that lead to cachexia research advancement.

Consideration of Cancer Type Effects on Cancer Cachexia Patient Outcomes

We found that many CC-CTx have relatively small samples sizes, with most CTx in this review recruiting 100 participants or fewer. CTx on CC require many clinical assessments in patients who are often unwilling or unable to contribute to research, and thus it can be challenging to recruit patients on a large scale. However, efforts to recruit larger samples sizes could increase the ability to better understand CC in diverse populations and achieve statistical power required for subgroup analyses. Additionally, almost one-third of CTx encompassed in the present work included more than one cancer type in the study population. Recently, it has become more apparent that different cancer types likely exhibit different patterns of tissue wasting and progression. This is clear not only in clinical findings, but also in preclinical models of CC where different tumor types exhibit mechanistic differences during disease development and progression (15). Thus, combining different cancer types without offering stratified analyses likely conceals cancer type-specific changes. However, we report that 41.5% of completed CTx and 64.5% of active CTx focused on a single cancer type, suggesting the evolving knowledge of varying clinical cancer characteristics and treatments has informed the design of CTx to improve our understanding of cancer type-specific CC outcomes. In addition, although CC is commonly diagnosed at advanced cancer stages, 76.4% of CTx included in this review did not report a specific cancer stage. Moreover, 73.3% of the studies incorporated in this analysis were interventional. Consequently, the lack of consideration for cancer stage as a clinical variable may skew the results of the interventions, particularly by overlooking pre-cachectic states in which knowledge remains limited.

Growing Focus on Exercise Interventions in Cancer Cachexia Clinical Trials

The use of pharmaceutical approaches to treat or prevent CC remains the most popular intervention among CC-CTx. Some of them report promising results, ameliorating some of the cachexia signs, such as Anamorelin and Ponsegromab (23, 28, 29). We observed a growing focus on exercise interventions in the study of CC, either alone or in combination with other treatment paradigms in recent years. As demonstrated by Schink et al. (NCT02293239) (30), a multimodal approach utilizing whole-body electromyostimulation (WB-EMS) combined with a light dynamic exercise training program alongside nutritional support, led to significant increases in skeletal muscle mass, body weight, and Karnofsky performance index over 12 weeks of training compared to the cancer control group (30). Highlighting exercise as a clinically relevant and promising strategy to mitigate the effects of CC. Additionally, there was a relative increase in the measure of physical function and quality of life, reinforcing the importance of maintaining muscle quality to enhance well-being in patients with CC. Along with a growing understanding of the molecular mechanisms of tissue wasting informed by preclinical studies, we observed an increase in the use of molecular measures in CTx. Broadly, we observed wide variation in the outcome measures reported, even those non-invasive, affecting the ability to analyze systematic reviews reinforcing clinical conclusions.

Body Weight is Underutilized as an Outcome in Cancer Cachexia Assessment

Although body weight and composition are fundamental measures of CC, we identified a surprisingly low frequency of studies reporting body weight (42.4%) and body composition (62.3%). Indeed, body weight loss utility may be enhanced when considered alongside other metrics, as demonstrated by Martin and collaborators (31), a BMI-adjusted weight-loss grading system (grades 0 to 4) that accounts for median overall survival and unadjusted estimated hazard

ratios (31). With more accurate tools for body composition measurement, such as CT and MRI, recent studies have brought attention to body composition changes across the cancer and treatment continuum within certain CC-associated cancer types (32, 33). Moreover, body composition, reported by CT, is often a primary outcome of CC-CTx, and sexual dimorphisms in the distribution of fat and muscle tissue in the thoracic and lumbar compartments must therefore be considered in the interpretation of body composition assessment. We found that active CTx are more frequently using these measurement tools, which will provide the field with a better understanding of body compositional changes during disease progression. In light of these findings, consistency of diagnostic criteria and outcome reporting across future CTx are essential in advancing our understanding of CC and improving clinical outcomes. To address this need, the Cancer Cachexia Society has convened a CTx Advisory Board, a multidisciplinary group of CC experts to provide transparent guidance on clinical trial design through a confidential and comprehensive review process.

Conclusions

Overall, a substantial gap persists in our understanding of CC in non-white and female populations. The report of CC definition and transparency in diagnostic criteria, along with the absence of stratified variables such as cancer type and biological sex are deficient, complicating the comparison and interpretation of CTx results. Lastly, the arrival of new techniques and methodologies used for cachexia assessment reinforces the need for a regularly revised and updated consensus definition and diagnosis criteria to align with new research findings and cutting-edge technology.

Limitations

In the findings we present in this review article it was challenging to determine the setting in which patients are recruited (e.g. oncology, palliative care) due to inconsistencies in reporting of patient population data and disease characteristics, which may influence the characteristics of the populations recruited for these studies.

Assessment of active, completed, and terminated CTx in this review reveals both the recent advancements and remaining gaps in clinical CC research. Addressing the lack of subgroup analyses based on biological sex is essential for comprehensive understanding of the differences in the development and progression of CC between males and females. Similarly, investigating the diverse manifestations of CC among various racial and ethnic groups is crucial for eliminating health disparities and developing treatment options that are effective in diverse populations. Standardizing CC diagnostic criteria across future clinical trials can enhance the reliability and effective comparability of trial findings. Additionally, small and heterogeneous study samples make drawing conclusions challenging, emphasizing a need for larger recruitment and modified trials designs that minimize the combination of cancer types, staging, and concurrent therapies within study populations. Current trends in intervention methods mirror advancing knowledge of CC, with corresponding changes in outcome measures. However, significant gaps and inconsistencies persist creating a dire need for continued improvement. By addressing these issues and proposing more effective and standardized study designs, we aim to contribute to ongoing advancement of our understanding of CC and ultimately improve patient outcomes.

Abbreviations

AWGS - Asian Working Group for Sarcopenia

BIA - Bioelectrical impedance analysis

BMI - Body mass index

CC – Cancer cachexia

CT - Computed tomography

CTx – Clinical trials

DXA - Dual energy x-ray absorptiometry

ECOG - Eastern Cooperative Oncology Group

EORTC QLQ - European Organization for the Research and Treatment of Cancer QoL Questionnaire

ESAS - Edmonton Symptom Assessment Score (ESAS)

ESPEN - European Society for Clinical Nutrition and Metabolism

EWGSOP2 - European Working Group on Sarcopenia in Older People

FAACT - Functional Assessment of Anorexia/Cachexia Treatment

MUST - Malnutrition Universal Screening Tool

NIH – National Institutes of Health

QoL - Quality of life

WB-EMS - Whole-Body Electromyostimulation

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

Correspondence and requests for materials should be addressed to Nicholas P. Greene.

Competing interests

he authors declare that they have no competing interests.

Funding

NHLBI T32- HL076122-18 (DBS).

Authors' contributions

ARC: drafting all the figures and final manuscript, reviewing, and editing. **KP:** creating the database, drafting the manuscript, reviewing, and editing. **DBS:** creating figures, writing, reviewing, and editing. **BH**: conceptualization, reviewing, and editing. **NPG:** conceptualization, resources, supervision, reviewing and editing. All authors reviewed and approved the final manuscript.

Acknowledgements

The authors thank all the faculty, staff, and students of the Exercise Science Research Center at the University of Arkansas.

Authors' information

[1]Cachexia Research Laboratory, Exercise Science Research Center, Department of Health, Human Performance and Recreation, University of Arkansas, Fayetteville AR

[2]Department of Medicine, University of Vermont College of Medicine, Burlington, VT, United States

[3]Public Health Program, Department of Health, Human Performance and Recreation, University of Arkansas, Fayetteville AR

References

1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229-63.
2. Society AC. Cancer facts & figures 2023. Atlanta: American Cancer Society; 2023.
3. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489-95.
4. Stewart GD, Skipworth RJ, Fearon KC. Cancer cachexia and fatigue. Clin Med (Lond). 2006;6(2):140-3.
5. Kilgour RD, Vigano A, Trutschnigg B, Lucar E, Borod M, Morais JA. Handgrip strength predicts survival and is associated with markers of clinical and functional outcomes in advanced cancer patients. Supportive Care in Cancer. 2013;21(12):3261-70.
6. Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998;34(4):503-9.
7. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern cooperative oncology group. Am J Med. 1980;69(4):491-7.
8. Karuppannan M, Muthanna FMS, Mohd Fauzi F. Breaking Down Cachexia: A Narrative Review on the Prevalence of Cachexia in Cancer Patients and Its Associated Risk Factors. Nutr Cancer. 2024;76(5):404-18.
9. Holmes S. Understanding cachexia in patients with cancer. Nursing Standard (through 2013). 2011;25(21):47-56; quiz 8.
10. Vagnildhaug OM, Balstad TR, Almberg SS, Brunelli C, Knudsen AK, Kaasa S, et al. A cross-sectional study examining the prevalence of cachexia and areas of unmet need in patients with cancer. Supportive Care in Cancer. 2018;26(6):1871-80.
11. Bruera E. Anorexia, cachexia, and nutrition. BMJ ens. 1997;315:1219-22.
12. Baracos VE. Bridging the gap: are animal models consistent with clinical cancer cachexia? Nat Rev Clin Oncol. 2018;15(4):197-8.
13. Ballarò R, Costelli P, Penna F. Animal models for cancer cachexia. Curr Opin Support Palliat Care. 2016;10(4):281-7.
14. Zhong X, Zimmers TA. Sex Differences in Cancer Cachexia. Current Osteoporosis Reports. 2020;18(6):646-54.
15. Silva FMd, Cabrera AR, Greene NP. Exploring Heterogeneity: A Dive into Pre-Clinical Models of Cancer Cachexia. American Journal of Physiology-Cell Physiology.0(0):null.
16. Olaechea S, Liu A, Sarver B, Gilmore LA, Alvarez C, Yazdanbakhsh K, et al. Racial, Ethnic, and Socioeconomic Characteristics Independently Predict for Cachexia Risk and Associated Survival Outcomes in Stage IV NSCLC: A Brief Report. JTO Clinical and Research Reports. 2023;4(4):100496.
17. Lau SKM, Gannavarapu BS, Carter K, Gao A, Ahn C, Meyer JJ, et al. Impact of Socioeconomic Status on Pretreatment Weight Loss and Survival in Non-Small-Cell Lung Cancer. J Oncol Pract. 2018;14(4):e211-e20.
18. Permuth JB, Clark Daly A, Jeong D, Choi JW, Cameron ME, Chen DT, et al. Racial and ethnic disparities in a state-wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor to observed inequities. Cancer Med. 2019;8(6):3314-24.
19. Permuth JB, Park MA, Chen D-T, Basinski T, Powers BD, Gwede CK, et al. Leveraging real-world data to predict cancer cachexia stage, quality of life, and survival in a racially and

ethnically diverse multi-institutional cohort of treatment-naïve patients with pancreatic ductal adenocarcinoma. Frontiers in Oncology. 2024;14.
20. Chen L-K, Woo J, Assantachai P, Auyeung T-W, Chou M-Y, Iijima K, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. Journal of the American Medical Directors Association. 2020;21(3):300-7.e2.
21. Arends J, Baracos V, Bertz H, Bozzetti F, Calder PC, Deutz NEP, et al. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr. 2017;36(5):1187-96.
22. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31.
23. Garcia JM, Boccia RV, Graham CD, Yan Y, Duus EM, Allen S, et al. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol. 2015;16(1):108-16.
24. Lee E, Wen P. Gender and sex disparity in cancer trials. ESMO open. 2020;5:e000773.
25. Institute of Medicine Board on Population H, Public Health P. The National Academies Collection: Reports funded by National Institutes of Health. Sex-Specific Reporting of Scientific Research: A Workshop Summary. Washington (DC): National Academies Press (US)

Copyright © 2012, National Academy of Sciences.; 2012.
26. Snoke DB, Atwood GS, Bellefleur ER, Stokes AM, Toth MJ. Body composition alterations in patients with lung cancer. Am J Physiol Cell Physiol. 2025;328(3):C872-C86.
27. Riner AN, Girma S, Vudatha V, Mukhopadhyay N, Skoro N, Gal TS, et al. Eligibility Criteria Perpetuate Disparities in Enrollment and Participation of Black Patients in Pancreatic Cancer Clinical Trials. J Clin Oncol. 2022;40(20):2193-202.
28. Groarke JD, Crawford J, Collins SM, Lubaczewski S, Roeland EJ, Naito T, et al. Ponsegromab for the Treatment of Cancer Cachexia. N Engl J Med. 2024;391(24):2291-303.
29. Currow D, Temel JS, Abernethy A, Milanowski J, Friend J, Fearon KC. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Ann Oncol. 2017;28(8):1949-56.
30. Schink K, Herrmann HJ, Schwappacher R, Meyer J, Orlemann T, Waldmann E, et al. Effects of whole-body electromyostimulation combined with individualized nutritional support on body composition in patients with advanced cancer: a controlled pilot trial. BMC Cancer. 2018;18(1):886.
31. Martin L, Senesse P, Gioulbasanis I, Antoun S, Bozzetti F, Deans C, et al. Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. 2015;33(1):90-9.
32. Al-Sawaf O, Weiss J, Skrzypski M, Lam JM, Karasaki T, Zambrana F, et al. Body composition and lung cancer-associated cachexia in TRACERx. Nat Med. 2023;29(4):846-58.
33. Babic A, Rosenthal MH, Sundaresan TK, Khalaf N, Lee V, Brais LK, et al. Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer. Nat Commun. 2023;14(1):4317.

Figure Legends

Figure 1. Demographics reported in clinical trials completed with results published from 2004-2023. a) Percentage of clinical trials including demographic data for age, biological sex, race, and ethnicity in the study population. **b)** Percentage of females and males included in clinical trials with reported results across years by clinical trial completion date (2004-2023). **c)** Percentage of White, Black, and Other races reported; others include 0.09% Native Hawaiian/Pacific Islander, 0.52% Asian, 0.91% Pardo, and 2.56% unknown (data not shown). "Fearon" marker indicates the year of the publication of the cancer cachexia consensus definition. "Sex as Biological Variable" indicates the year of the NIH expectation to consider sex as a biological variable in NIH-supported preclinical and clinical studies.

Figure 2. Cancer cachexia diagnostic criteria used in trials from 1995-2024. a) Studies that used weight loss greater than 5% in less than six months as their criteria, or weight loss greater than 2% in individuals already showing depletion with body mass index (BMI) <20 kg/m^2 or skeletal muscle mass loss were classified as 'Fearon'; studies defining cachexia in a different way were classified as 'Other'. **b)** Distribution of the cachexia definitions used across years.

Figure 3. Study population and approach. a) Cancer type and **b)** stages reported in clinical trials related to cancer cachexia. **c)** Clinical trials approach. LOESS (locally weighted smoothing) regression analysis from pharmacological (drugs), exercise, dietary, and multimodal interventions across years (1995-2024) investigated in cancer cachexia clinical trials. "Fearon" marker indicates the year of the publication of the cancer cachexia consensus definition.

Figure 4. Clinical trials outcomes across years (1995-2024). Number of trials and LOESS (locally weighted smoothing) regression analysis from **a)** body weight, **b)** body composition, **c)** physical function, **d)** quality of life (QoL), **e)** nutrition and appetite, **f)** molecular measures, **g)** safety and tolerability, and **h)** survival measured in cancer cachexia clinical trials. "Fearon" marker indicates the year of the publication of the cancer cachexia consensus definition.

Supplementary Information

Supplemental File 1. List of clinical trials included in this review. Identification number is the NCT code under which the clinical trial is registered in ClinicalTrials.gov. The status is completed with (w/) results, completed without (w/o) results, still active, or withdrawn (terminated) before completion.

Supplemental File 2. Summary of search results by terms and status of the clinical trials.

Supplemental File 3. This table list the reasons for withdrawn or anticipated termination before completion of clinical trials studying cancer cachexia registered in ClinicalTrials.gov.

Supplemental File 4. Phases and status of clinical trials exploring cancer cachexia effects on ClinicalTrials.gov in Phase1-4 or No Phase.

Supplemental File 5. Clinical trials registered on ClinicalTrials.gov that used Fearon's definition or any other criteria to diagnose cancer cachexia within each status.

Supplemental File 6. Clinical trials stratified by clinical trial status studying cachexia but classified under other terms different than “cachexia”.

Supplemental File 7. A) Study population of clinical trials registered on ClinicalTrials.gov investigating cancer cachexia. **B)** Population dropout percentage within each clinical trial.

Supplemental File 8. Cancer type and cancer stage of clinical trials registered on ClinicalTrials.gov investigating cancer cachexia.

Supplemental File 9. Clinical trials approach and intervention utilized: drug testing, dietary supplement, exercise/physical therapy, a combination of 2 or more interventions (multimodal), others, or none or non-stated intervention of clinical trials registered on ClinicalTrials.gov investigating cancer cachexia.

Supplemental File 10. Pharmaceutical drugs and dietary supplements evaluated in CTx between 1995-2024.

Supplemental File 11. Biomarkers measured in cancer cachexia clinical trials registered on ClinicalTrials.gov.

Supplemental File 12. Outcome measures of cachexia in the clinical trials registered on ClinicalTrials.gov by status: Body weight, body composition, physical function, quality of life, nutrition/appetite, molecular, safety and tolerability, and survival.

Supplemental File 13. Measurement tools used to investigate cachexia by the clinical trials registered on ClinicalTrials.gov by status.


a
Age
Biological Sex
Race
Ethnicity
100%
94.2 %
5.8 %
32.7 %
67.3 %
9.6 %
90.4 %
0
25
50
75
100
%
Reported
Not_Reported
c
4.1 %
92.6 %
3.3 %
White
Black
Other
b
Fearon
Sex as Biological Variable
Percentage
100
75
50
25
0
1995
2000
2005
2010
2015
2020
2024
Year
Females
Males


a
33.5 %
28.3%
38.2%
Not_specified
Other
Fearon
b
100
75
50
25
0
Percentage of Trials
No trials reported from (1996-1999)
1995
2000
2005
2010
2015
2020
2024
Year


a
Lung
15.2%
Not Specified
24.1%
Pancreas
11.5%
8.9%
Gastric
5.2%
3.7%
5.8%
8.9%
5.2%
11.5%
4-types or more
3-types
2-types
Colorectal
Head and Neck
Others
b
Others
5.7%
Stage III-IV
12.6%
Stage II-IV
3.7%
Stage I-IV
1.6%
76.4%
Not Specified
c
4
3
2
1
0
Trials
Fearon
1995
2000
2005
2010
2015
2020
2024
Year
Drug
Exercise
Dietary
Multimodal

a
Body Weight
No. Trials
Year
Fearon
Body_weight
Total
b
Body Composition
Body_composition
Total
c
Physical Function
Physical_function
Total
d
QoL
QoL
Total
e
Nutrition & Apetite
Nutrition_Apetite
Total
f
Molecular Measures
Molecular_measures
Total
g
Safety & Tolerability
Safety_Tolerability
Total
h
Survival
Survival
Total

Supplemental File 1 - List of clinical trials

Identification Number	Status	Study Title
NCT00467844	Completed w/ Results	Double-Blind, Placebo-Controlled, Dose-Finding Study of the Effect of GTx-024 on Muscle Wasting (Cachexia) in Patients with Cancer
NCT00815685	Completed w/ Results	A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients with Cancer Cachexia
NCT01433263	Completed w/ Results	A Randomized, Double-blind, Placebo-controlled Multi-center Study of BYM338 for Treatment of Cachexia in Patients with Stage IV Non-small Cell Lung Cancer or Stage III/IV Adenocarcinoma of the Pancreas
NCT00527319	Completed w/ Results	A Pilot Open Label Randomized Controlled Study to Evaluate the Dose Tolerance Safety and Efficacy of VT-122 Regimen for the Treatment of Cachexia in Subjects with Stage IV Non-Small Cell Lung Cancer
NCT02968979	Completed w/ Results	Cross-sectional, Multicentric, Non-interventional Study to Assess the Frequency and the Management of Cachexia and Associated Symptoms in Patients with Non-small Cell Lung Cancer
NCT00878995	Completed w/ Results	Nutrition and Anabolic Interventions in Squamous Cell Carcinoma
NCT01395914	Completed w/ Results	Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
NCT01387282	Completed w/ Results	Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
NCT01387269	Completed w/ Results	Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
NCT01355497	Completed w/ Results	Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients with Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
NCT01355484	Completed w/ Results	Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients with Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy

… Supplemental File 1 Continue

Identification Number	Status	Study Title
NCT00513357	Completed w/ Results	A Randomized Clinical Trial of Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients
NCT04299048	Completed w/ Results	A Phase 1B, 12-Week, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following repeated subcutaneos administration of PF-06946860 in Patients with Cancer and Cachexia
NCT00040885	Completed w/ Results	Docetaxel and Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
NCT03524755	Completed w/ Results	Effects of a Progressive Resistance Training in Cachectic Cancer Patients During Radiotherapy - a Randomized Controlled Pilot Trial
NCT02138422	Completed w/ Results	A Double Blind, Placebo Controlled Pivotal Phase III Study Evaluating Xilonix™ in Symptomatic Colorectal Cancer Patients Refractory to Standard Therapy
NCT00081250	Completed w/ Results	Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
NCT02359123	Completed w/ Results	Cannabics Capsules as Treatment to Improve Cancer Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients- Pilot Study
NCT03254173	Completed w/ Results	Mirtazapine for Treatment of Cancer Associated Anorexia-cachexia: A Randomized Controlled Clinical Trial
NCT02400398	Completed w/ Results	A Longitudinal, Single Institution Study Evaluating Weight Stability in Advanced Pancreatic Cancer Patients with Cachexia Who Are Receiving Enteral Feeding
NCT03207724	Completed w/ Results	A Phase I Study of Onivyde and 5-FU in Combination with Xilonix for Advanced Pancreatic Cancer with Cachexia

… Supplemental File 1 Continue

Identification Number	Status	Study Title
NCT04208334	Completed w/ Results	A Double-blind, Placebo-controlled Randomized Trial Phase II Evaluating the Effect of Curcumin for Treatment of Cancer Anorexia-Cachexia Syndrome in Patients with Stage III-IV of Head and Neck Cancer
NCT03283488	Completed w/ Results	Randomized, Double-blind Clinical Trial of the Use of Mirtazapine Versus Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.
NCT04585841	Completed w/ Results	The Effect of Medical Cannabidiol on Lean Body Mass in Patients Receiving Oxaliplatin or Paclitaxel Based Chemotherapy
NCT00031707	Completed w/ Results	Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Megestrol Acetate (Megace) Versus an N-3 Fatty Acid (EPA) Enriched Nutritional Supplement Versus Both for the Treatment of Cancer Cachexia and Anorexia
NCT00919659	Completed w/ Results	Parenteral Nutrition Support for Patients with Pancreatic Cancer. A Phase II Study.
NCT00329615	Completed w/ Results	Insulin Treatment in Cancer Cachexia: Effects on Survival, Metabolism and Physical Functioning. A Randomized Prospective Study.
NCT00219817	Completed w/ Results	Safety and Efficacy of RC-1291 HCl in Patients with Cancer Related Anorexia and Weight Loss
NCT00267358	Completed w/ Results	Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.
NCT00066248	Completed w/ Results	The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children with Cancer/Treatment Related Cachexia
NCT00046904	Completed w/ Results	Phase III Placebo-Controlled, Randomized, Double-Blind Comparison of Etanercept (Enbrel) Versus Placebo for the Treatment of Cancer-Associated Weight Loss and Anorexia
NCT00053053	Completed w/ Results	A Double-Blind Study of Nutritional Intervention for The Treatment of Cancer Cachexia Using Juven® Nutritional Supplement
NCT00933361	Completed w/ Results	Individual Dose-escalated Bi-daily sc Ghrelin in Cancer Cachexia: A Phase I/II Study

… Supplemental File 1 Continue

Identification Number	Status	Study Title
NCT00477919	Completed w/ Results	E-MOSAIC: A Multicenter Randomized Controlled Phase III Study of Longitudinal Electronic Monitoring of Symptoms and Syndromes Associated with Advanced Cancer in Patients Receiving Anticancer Treatment in Palliative Intention
NCT00895726	Completed w/ Results	Open-Label, Pilot Phase I/II Study of the Efficacy and Safety of APD209 in Patients with Cachexia and Advanced Malignancy
NCT00489593	Completed w/ Results	Phase I Dose-Finding Pilot Study of the Safety and Tolerability of Olanzapine in Patients with Advanced Cancer and Weight Loss
NCT01596933	Completed w/ Results	Multi-centric, Placebo-controlled Trial of Omega-3 Fatty Acid Supplementation in Weight Maintenance and Preservation of Lean Body Mass, in (Pre)Cachectic Head and Neck Cancer Patients, Undergoing Curative Radio (Chemo)Therapy
NCT02350855	Completed w/ Results	To Study the Impact of Nutritional Intervention in Delaying the Progression of Cachexia to Refractory Cachexia in Female Cancer Patients: A Study Based in India
NCT01419145	Completed w/ Results	A Feasibility Study of Multimodal Exercise/Nutrition/Anti-inflammatory Treatment for Cachexia - the Pre-MENAC Study
NCT01622036	Completed w/ Results	The PreMiO Study: The Prevalence of Malnutrition in Oncology.
NCT01604642	Completed w/ Results	Role of Activin A (ActA) in the Human Cancer Cachexia
NCT02561143	Completed w/ Results	To Evaluate the Effectiveness of Nutritional Counselling and "Improved Atta" Supplementation in Delaying Progression of Cachexia to Refractory Cachexia in Adult Cancer Patients in Indian Population
NCT02148159	Completed w/ Results	Impact of Mechanism Based Acupuncture Intervention to Improve Weight Loss in GI Cancer Patients with Cachexia
NCT02515032	Completed w/ Results	A 12-week Double Blind, Placebo Controlled, Randomised Pilot Study Assessing Safety and Tolerability of Nutrifriend Cachexia in Patients Diagnosed with Non-Small Cell Lung Cancer (NSCLC) With Involuntary Weight Loss
NCT02293239	Completed w/ Results	Effects of Whole-Body Electromyostimulation (WB-EMS) Combined with Individualized Nutritional Support on Patients with Malignant Disease Undergoing Curative or Palliative Anti-cancer Treatment

… Supplemental File 1 Continue

Identification Number	Status	Study Title
NCT01614990	Completed w/ Results	Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients with Cancer Cachexia
NCT05837741	Completed w/ Results	Standard Hypercaloric, Hyperproteic vs Leucine-enriched Oral Supplements in Patients with Cancer-induced Sarcopenia
NCT02877368	Completed w/ Results	Sarcopenia in Patients with Gastrointestinal Stromal Tumours
NCT02779868	Completed w/ Results	Effect of Omega-3 Supplementation on Body Composition, Functional Capacity, Inflammatory Profile and Quality of Life in Cervix Cancer Patients Undergoing Chemoradiotherapy
NCT01484821	Completed w/ Results	Assessment of in Vivo Skeletal Muscle Viscoelasticity (ARFI Imaging) With Aging and Cancer (CAPARFI)
NCT04714203	Completed w/ Results	Assessment of the Prevalence of Sarcopenia in Early Palliative Cancer Patients
NCT01564693	Completed w/ Results	Neuroimaging of Hypothalamic Activity During Cancer Anorexia
NCT04153019	Completed w/o Results	psycho-educational and Rehabilitative Intervention for the Oncological Patient with Cachexia and his Caregiver: A Feasibility Study
NCT02199912	Completed w/o Results	ANC2 Pilot Study of the Relationship Between Clinical and Paraclinical Markers During Situations of Cachexia and Pre-cachexia in Patients Over 70 Years with Colorectal Surgery
NCT03583177	Completed w/o Results	Study of Muscle Wasting Mechanisms and Biomarkers in Hemodialysis Patient
NCT03144128	Completed w/o Results	The Contribution of Vitamin D to Muscle Metabolic Function in Cancer Cachexia
NCT04802486	Completed w/o Results	Evaluating the Effects of a 12 Week Home-based Exercise Intervention on Physical Performance in Patients with Cancers of the Gastrointestinal Tract with Pre- Cachexia or Cachexia: A Pilot Study
NCT02983500	Completed w/o Results	Tablet-based Prospective Patient Reported Outcomes (PRO) Registry in Patients with Advanced NSCLC or Advanced Pancreatic Cancer with Focus on Cancer Cachexia

… Supplemental File 1 Continue

Identification Number	Status	Study Title
NCT03012139	Completed w/o Results	Cancer-Associated Muscle Atrophy and Weakness: An Investigation of Etiology
NCT04643613	Completed w/o Results	Role of Ready to Drink Nutritional Formula (Protison Enriched With ω-3 FA and BCAA) Supplemented by Nasogastric Tube Feeding in Various Cancer Patients: A Randomized Clinical Trial
NCT03958032	Completed w/o Results	Effects of Sarcopenia on Early Postoperative Outcomes in Patients Undergoing Surgical Treatment for Gastric Cancer
NCT03881826	Completed w/o Results	Investigation of the Gut Microbiota in Patients with Acute Myeloid Leukemia
NCT05023499	Completed w/o Results	Perioperative Glutamine Supplementation Restores Atrophy of Psoas Muscle in Gastric Adenocarcinoma Patients Undergoing Gastrectomy
NCT04131426	Completed w/o Results	Evaluating the Effects of Dietary Supplementation with Remune on Cancer Associated Weight and Muscle Loss with and Without Exercise: A Randomized Pilot Feasibility Study.
NCT03743051	Completed w/ Results	A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00014248	Completed w/o Results	A Phase I Study and Pharmacokinetics of Adenosine 5'- Triphosphate (ATP) When Administered by Intravenous Infusion on A Multiple Weekly Dose Schedule To Patients With Advanced Malignancies (Solid Tumors)
NCT00004912	Completed w/o Results	Phase II Trial of Progressive Resistance Training with Megestrol Acetate for the Treatment of Cancer-Related Weight Loss
NCT00378131	Completed w/o Results	A 12-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Phase II Study Comparing the Safety, Tolerability and Beneficial Effects of Daily Doses of RC-1291 and Placebo in Patients with Cancer Anorexia/Cachexia

… Supplemental File 1 Continue

Identification Number	Status	Study Title
NCT00094562	Completed w/o Results	AAFA™ Fish Oil Nutritional Supplementation to Maintain Body Weight in Patients with Disease-Related Weight Loss
NCT00486304	Completed w/o Results	Determine the safety of the antioxidant-deficient diet (ADD) in controlling cachexia in patients with oropharyngeal cancer receiving chemoradiotherapy.
NCT00899158	Completed w/o Results	Role of Caspase-3, Phosphatidylinositol-3 Kinase (PI3K), and 3-methylhistidine (3-MH) in the Pathophysiology of Skeletal Muscle Loss in Weight-losing Pancreas Cancer Patients
NCT00866970	Completed w/o Results	A Phase II Study to Determine the Safety, Efficacy, and Pharmacokinetics of Multiple Intravenous Doses of ALD518 80 mg, 160 mg, and 320 mg Versus Placebo Administered to Patients with Non-Small Cell Lung Cancer-Related Fatigue and Cachexia
NCT01136083	Completed w/o Results	Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients
NCT00994669	Completed w/o Results	Development of a Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients
NCT01127386	Completed w/o Results	Effect of Lenalidomide (Revlimid®) in Solid Tumour Patients with Inflammatory Cancer Cachexia Syndrome on Lean Body Mass and Muscle Strength: A Multicenter, Proof-of-concept Study of Fixed Dose or CRP-response-guided Dose of Lenalidomide in Relation to New Standard Basic Cachexia Management (Receiving Placebo).
NCT01939340	Completed w/o Results	Prevalence and Impact of Cachexia in Cancer Patients Undergoing Chemotherapy
NCT01238107	Completed w/o Results	A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase II Clinical Study to Evaluate Doses of MT-102 in Subjects with Cachexia Related to Stage III and IV Non-small Cell Lung Cancer and Colorectal Cancer

… Supplemental File 1 Continue

Identification Number	Status	Study Title
NCT01533909	Completed w/o Results	Development of a Screening Tool to Detect and Stage Cachectic Cancer Patients
NCT01694602	Completed w/o Results	Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase 2
NCT04699760	Completed w/o Results	Single-blinded, Randomized, Controlled Trial About the Effects of n-3 LCPUFAs on Weight and Functional Status in Patients with Colorectal Cancer.
NCT03162042	Completed w/o Results	Role of Myostatin, Activin A and Follistatin Cachexia of ENT Cancers
NCT03263520	Completed w/o Results	Impact of the Use of Nandrolone on the Treatment of Malnutrition Induced by Cancer
NCT05264038	Completed w/o Results	A Phase 1, Randomized, Double-Blind, Dose-Ranging, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics Effects of OC514 in Healthy Adult Volunteers
NCT05323604	Completed w/o Results	Impact of Sarcopenia on Post-operative Course for Cancer Patients Operated of Colorectal Surgery Using a Simple Measurement Method of the Psoas Muscle Surface Area
NCT05583292	Completed w/o Results	The Effectiveness of ASA, SORT and Sarcopenia Indices in Estimating Mortality and Morbidity in Gastrointestinal Tumour Surgery
NCT03032224	Completed w/o Results	Analysis of Sarcopenia and Body Composition in Relation to Outcome in a Cohort of Patients with Esophageal Cancer or Cancer of the Gastroesophageal Junction Before and After Surgery with Curative Intent
NCT03915288	Completed w/o Results	Moderate Continuous Training Versus HIIT on Cardiometabolic and Psychosocial Variables in Cancer Stadium II. Control Randomized Trial
NCT03770117	Completed w/o Results	A Pilot Study of the Effect of Prehabilitation on Markers of Sarcopenia in Patients Undergoing Pancreatoduodenectomy for Malignant Disease

… Supplemental File 1 Continue

Identification Number	Status	Study Title
NCT03962140	Completed w/o Results	Computed Tomography Assessment of Body Fat Distribution in Endometrial Cancer Patients
NCT04815551	Completed w/o Results	A Phase 1, First-in-human, Randomized, Placebo Controlled, Double Blind, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AV-380 in Healthy Subjects
NCT03960034	Completed w/o Results	Cachexia in Advanced NSCLC Patients: Diagnosis, Characterization, Prognosis, Functional Implications and Validation of Skeletal Muscle Disfunction Markers
NCT03058107	Completed w/o Results	Tight Caloric Control in the Cachectic Oncologic Patient (TiCaCONCO or CoCooN) Can Stabilize Body Weight, Thereby Reducing Morbidity and Mortality: Validation of the Pilot Study - A Randomized Controlled Double-Blind Trial
NCT04803305	Completed w/o Results	A 6-Week, Randomized, Double-blind, Sponsor-open Study to Assess the Effect of Repeated Sucutaneous Administration of PF-06946860 on Appetite in Participants with Advanced Cancer and Cachexia, Followed by an 18-week Open-Label Treatment Period
NCT02330926	Completed w/o Results	A Randomised, Open-label Trial of a Multimodal Intervention (Exercise, Nutrition and Antiinflammatory Medication) Plus Standard Care Versus Standard Care Alone to Prevent/Attenuate Cachexia in Advanced Cancer Patients Undergoing Chemotherapy
NCT00060502	Completed w/o Results	A Phase II, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Anti-TNF a Monoclonal Antibody (Infliximab) to Treat Cancer-Related Cachexia in Subjects with Pancreatic Cancer.
NCT04161794	Completed w/o Results	Multimodal Intervention (Dietary Counselling, Fish Oil and Physical Training) for Patients with Non-small Cell Lung Cancer, a Feasibility Study
NCT02500004	Completed w/o Results	Brown Adipose Tissue Activity and Energy Metabolism in Cachexia Induced by Cancer or Chronic Disease

… Supplemental File 1 Continue

Identification Number	Status	Study Title
NCT00196885	Completed w/o Results	Effect of N-Acetylcysteine on Skeletal Muscle in Cachectic Cancer Patients Undergoing a Resistance Training Program (Phase 2 Study)
NCT03743064	Completed w/o Results	A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT03316157	Completed w/o Results	Exercise and Nutritional Rehabilitation in Patients with Cancer, Randomised (1:1) Unblinded Feasibility Trial of a Rehabilitation Programme (Exercise and Nutrition) Versus Waiting List Control, in Patients with Advanced Cancer
NCT00003077	Completed w/o Results	Phase I/II Trial of Omega-3 Fatty Acids for Cancer Cachexia
NCT03200639	Completed w/o Results	Comparison of High Intensity Interval Body Weight Training Versus Combined Training on Body Composition, Physical Function, Metabolic Risk and Inflammation in Postmenopausal Women with and Without Gynecological Cancer
NCT02788955	Completed w/o Results	Decreasing the Burden of Sarcopenia in Cancer Through Targeted Nutrition Intervention: A Feasibility Study
NCT06093009	Completed w/o Results	The Significance of Postoperative Muscle Wasting in Pancreatic Cancer
NCT02107664	Completed w/o Results	The Palliative Radiotherapy and Inflammation Study: Palliative Radiotherapy of Bone Metastasis. Classification, Inflammatory Biomarkers, and Longitudinal Clinical Follow-up
NCT03042442	Completed w/o Results	Relation Between Cachexia, Diabetes and periNeural Invasion in PANcreatic Cancer- Biomarkers Substudy
NCT05623852	Active	A Phase II Trial for Oligo-Fucoidan in Cancer Cachexia and Sarcopenia
NCT05376592	Active	Association of Genomic Polymorphisms with Cancer Cachexia in Subjects with Pancreatic Adenocarcinoma
NCT05865535	Active	A Phase 1 Dose Escalation Study of AV-380 in Combination with Standard of Care Chemotherapy in Metastatic Cancer Patients with Cachexia and Elevated GDF-15 Levels

… Supplemental File 1 Continue

Identification Number	Status	Study Title
NCT05912465	Active	The Role of 18F-FDG PET/CT in the Early Prediction of Cachexia in Lung Cancer Patients
NCT04127981	Active	A Pilot Bioimaging Trial of Cancer Cachexia
NCT05128318	Active	Study of the Tumor-adipose Tissue Dialogue: Role of Tumor Acidosis in the Induction of Adipocyte Lipolysis
NCT05731076	Active	Efficacy of Self-Management Support on Nutritional Status in Lung Cancer Patients with Cancer Cachexia Syndrome: A Randomized Clinical Trail
NCT06073431	Active	Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia
NCT05275075	Active	Pilot Trial to Identify microRNAs in Cachexia in Patients with Pancreatic Carcinoma
NCT05915325	Active	Physical Training for Elderly Cancer Patients with Cachexia (TEECH-01): A Prospective Clinical Trial
NCT04627376	Active	Effectiveness of a Multimodal Education and Support Program for the Prevention of Cancer Related Cachexia for Patients and Their Family Caregiver
NCT05606523	Active	Can Fecal Microbiota Transplantation of Cachectic Patients with Pancreas Cancer Impair Body Weight Gain in Germ-free Mice? The EXTRA Study
NCT04906746	Active	Pilot Study of Ruxolitinib in the Treatment of Cancer Cachexia
NCT04864431	Active	The Effect of Vitamin D on Factors Contributing Pre-Cachexia and Cachexia, a Study on Epithelial Ovarian Cancer
NCT05028192	Active	Mitochondria Preservation by Exercise Training: A Targeted Therapy for Cancer and Chemotherapy-induced Cachexia.
NCT04600154	Active	Effects of MS-20 on Gut Microbiota and Risk/Severity of Cachexia in Patients Receiving Chemotherapy for Pancreatic Cancer
NCT04469504	Active	Prehabilitaion Program for Sarcopenic Patients Prior to Pancreaticoduodenectomy for Periampullary Malignant Tumors

… Supplemental File 1 Continue

Identification Number	Status	Study Title
NCT06015971	Active	Omega-3 Enriched Supplements in the Nutritional Support of Patients with Gastrointestinal Cancer
NCT05294380	Active	Determination of Sarcopenia Risk and Related Factors in Pediatric Oncological Patients
NCT03641118	Active	Assessment of Measures of Sarcopenia and Whole-Body Physiology in Cancer Patients and Their Relationship to Surgical Outcome and Survival
NCT05833321	Active	Prospective Monocentric Study of the Detection of Sarcopenia in Clinical Practice in Patients with Ovarian or Endometrial Cancer Requiring Systemic Oncological Treatment
NCT05658263	Active	Bacterial Intestinal Gut Modification Around Cancer Surgery (BIG MACS) Diet
NCT02978521	Active	Effect of a Pulmonary Rehabilitation Program on Skeletal Muscle Mass, Pulmonary Function, Inflammatory Response and Overall Survival on Patients Diagnosed with Non-small-cell Advanced Cancer
NCT06203301	Active	The Relationships of Resistance Exercise, Walking, Myokine Secretion, Sarcopenia, Muscle Loss, Quality of Life, and Predictors in Cancer Patients Receiving Chemoradiotheray
NCT03256201	Active	Preoperative Exercise and Nutrition to Improve Pancreatic Cancer Outcomes by Targeting Sarcopenia: A Translational Pilot RCT
NCT05307367	Active	Identifying Molecular Factors Contributing to Cancer-associated Muscle Mass Loss and Providing Clinical Evidence for Exercise Mechanisms to Functionally Restore Muscle in Cancer
NCT06027242	Active	Oral Supplementation of Glutamine on Gastric Cancer Patients After Gastrectomy
NCT05778136	Active	Exercise in Lung Cancer Patients - Specific Training, Muscle Mass and Force Development
NCT05650827	Active	Feasibility and Effect of Resistance Training and Protein Supplementation in Patients with Advanced Gastroesophageal Cancer

… Supplemental File 1 Continue

Identification Number	Status	Study Title
NCT04899882	Active	Physical Fitness Impact of Early Physiotherapy Intervention with a Standardized Exercise Therapy Program in Adult Patients Receiving Intensive Induction Chemotherapy for Treatment of Acute Leukemia During Extended Hospitalization. Randomized Controlled Superiority Trial in Parallel Arms, Multicentric (KinHémo)
NCT05556239	Active	The Effect of Resistance Training in Patients with Malignant Lymphoma Undergoing Chemotherapy Treatment - the STAY STRONG TRIAL - a Randomized Controlled Trial.
NCT05899205	Active	Patient Recorded Indexing Measurements
NCT05257135	Active	Development of a Prospective Clinico-biological Database in Cachexia in Patients with Colon Cancer
NCT06250686	Active	Exercise and Nutrition Intervention in Ovarian Cancer - Development of a Care Concept and Evaluation in Routine Clinical Practice
NCT05642819	Active	Routine Evaluation of People Living with Cancer - Surgery
NCT05919147	Active	A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Neuroendocrine Effects of Pioglitazone in Patients with Advanced Non-Small-Cell Lung Cancer and Cachexia
NCT05336266	Active	IIT2021-16-Hendifar-KetoROCX: A Feasibility Study of Ketorolac Treatment for Cachexia in Patients with Advanced Pancreatic Ductal Adenocarcinoma
NCT04098237	Active	Pancreatic-enzyme Replacement Therapy with Pancreaze (Pancrelipase) Delayed-release in Addition to Standard of Care for Borderline Resectable, Locally Advanced, and Advanced Pancreatic Adenocarcinoma Patients (PANCAX-3) With Cachexia and Exocrine Pancreatic Insufficiency
NCT04844970	Active	A Randomized, Double-blind, and Placebo Controlled Multicenter Phase II Trial Evaluating Anamorelin in the Prevention of Cancer Induced-Weight Loss and Anorexia in Patients Receiving First-line Treatment of Advanced Pancreatic Cancer

… Supplemental File 1 Continue

Identification Number	Status	Study Title
NCT06207708	Active	Role of Baseline Sarcopenia in Determining Acute Toxicity for Head and Neck Cancer Patients Treated with Curative Hadrontherapy: A Prospective Monoinstitutional Study
NCT05194397	Active	Intensive Tailored Exercise Training With NAD+ Precursor Supplementation to Improve Muscle Mass and Fitness in Adolescent and Young Adult Hematopoietic Cell Transplant Survivors
NCT03982082	Active	Feasibility Study of Ultrasound to Evaluate Muscle-Glycogen Content in Patients with Cancer
NCT03851133	Active	The Florida Pancreas Collaborative Next-Generation Biobank: Reducing Health Disparities and Improving Survival for Pancreatic Cancer
NCT04090619	Active	Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Both Patients and Their Primary Caregivers Who Are Referred to an Outpatient Supportive Care Clinic
NCT05546476	Active	A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of Ponsegromab in Patients with Cancer, Cachexia, and Elevated concentrations of GDF-15, Followed by an Optional Open-Label Treatment Period (PROACC -1)
NCT03637816	Active	Qualitative Study on Experiences Related to Anorexia and the Effects of Anamorelin and Placebo in Advanced Non-Small-Cell Lung Cancer Patients with Anorexia-Cachexia: A Preliminary Study
NCT02567669	Active	Muscle Loss and Fatigue as a Consequence of Radiotherapy
NCT04065984	Active	BiCyCLE: Neuro-Muscular Electrical Stimulation (NMES) and Its Effect on Changes in Body Composition Following Surgery for Locally Advanced Rectal Cancer - a Single Centre Double Blind Randomised Controlled Phase II Clinical Trial

… Supplemental File 1 Continue

Identification Number	Status	Study Title
NCT03606317	Active	Retrospective Review of Cachexia in Lung and Gastrointestinal Cancer Patients
NCT03568019	Active	PET Avidity in Cachexia-Inducing Lung and Gastrointestinal Tumors
NCT04090619	Active	Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Both Patients and Their Primary Caregivers Who Are Referred to an Outpatient Supportive Care Clinic
NCT06166134	Active	Radiological Evaluation of Sarcopenia in Patient Received Chemotherapy
NCT05771207	Active	Effects of Soy Protein and Whey Protein on Muscle, Gut Microbiota and Clinical Outcome in Patients with Lung Cancer-related Sarcopenia（LCRS）: A Randomized, Double-blind, Controlled Clinical Study
NCT05710809	Active	The SaVe Project-Sarcopenia and Vertigo in Aging Patients with Colorectal Cancer
NCT06137508	Active	Cancer-associated Cachexia in Patients with Incurable Gastroesophageal Cancer
NCT06077734	Active	In Vitro Quality Assessment of Myogenic Stem Cells in Multiple Patient Groups with Confirmed Skeletal Muscle Atrophy to Study Their Potential for Autologous Stem Cell Therapy
NCT06007794	Active	Correlation Between Ultrasound-assessed Quadriceps Muscle Mass and Baseline Whole-body Densitometry Muscle Index in the Post-cancer Population (JUMP Research II)
NCT05954117	Active	Effect of Chemotherapy on Metabolic Flexibility in the Context of Cachexia in Cancers of the Esophagus and Gastroesophageal Junction
NCT05856500	Active	A Prospective Open Controlled Study of Creatine Combined with Curcumin in the Intervention of Early Cachexia in Upper Gastrointestinal Tumors

… Supplemental File 1 Continue

Identification Number	Status	Study Title
NCT05420259	Active	Influence of a Combined Dietary and Exercise Intervention on Cytokine Profile and NK Cell Activation in Cancer Patients Undergoing Neoadjuvant Treatment.
NCT06277986	Active	Clinical Value of Tumor Cell-derived Exosomal miRNA in Early Diagnosis of Gastric CancerCachexia
NCT03191955	Active	Biochemical and Functional Biomarkers of Cachexia in Cancer Patients
NCT00637728	Terminated	A Randomized, Double-blind, Placebo-controlled Study of Megestrol Acetate Concentrated Suspension for the Treatment of Cancer-associated Anorexia in Subjects with Lung or Pancreatic Cancer
NCT02515513	Terminated	The Role of Muscle Cachexia in Pancreatic Cancer
NCT04034745	Terminated	IIT2018-26 -Hendifar-NETCx: A Descriptive, Multicenter, Single-arm, Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain
NCT02877966	Terminated	Evaluation of the Effects of a Stoichiometric Mixture of Amino Acids (Amixea) on Lean Body Mass and Muscle Strengh of Patients with Unresectable Advanced Non-Small Cell Lung Cancer: A Randomized, Double Blind, Placebo-controlled, Multicenter Study
NCT03172403	Terminated	Skeletal Muscle Expression of Myostatin and Cancer of Digestive System Associated Cachexia (MYOCAC Study)
NCT03245658	Terminated	The Effect of Medical Cannabis Inpatients with Palliative Pancreatic Cancer
NCT01501396	Terminated	Treatment of Cancer Anorexia-cachexia Syndrome (CACS) With Mirtazapine and Megestrol Acetate
NCT00535015	Terminated	A Randomized, Double-Blind, Pilot Study Comparing the Safety and Efficacy of Betamarc Plus Chemotherapy to Chemotherapy Alone in the Prevention and Treatment of CACS in Patients with Advanced NSCLC

… Supplemental File 1 Continue

Identification Number	Status	Study Title
NCT01330823	Terminated	L-Carnitine in the Palliative Treatment of Advanced Pancreatic Cancer (CARPAN): A Prospective, Randomised, Placebo Controlled, Double Blinded, Multicentre Trial
NCT03720158	Terminated	Effect of Enteral Supplementation of Omega 3 Fatty Acids on the Quality of Life and Functionality of Patients with Head and Neck Squamous Cell Carcinoma Undergoing Radiotherapy
NCT01046383	Terminated	Effect of IMN1207 Versus Casein on, Weight Loss, Survival and Quality of Life in Non-small Cell Lung Cancer Patients During or Following Chemotherapy, Radiation or Surgery: A Multi-center Randomized, Double-blind Study - Phase III Trial
NCT01132547	Terminated	Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk
NCT03253029	Terminated	Use of Branched-chain Amino Acids in Cancer Cachexia
NCT02072057	Terminated	The RUXexia Trial: An Open-label Phase II Trial of Ruxolitinib in the Treatment of Cachexia in Patients with Tumor-Associated Chronic Wasting Diseases.
NCT01505764	Terminated	The Role of Ghrelin in Cancer Cachexia
NCT02416570	Terminated	Is Clarithromycin a Potential Treatment for Cachexia in People with Lung Cancer?
NCT00851448	Terminated	Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Lung Cancer Patients. A Randomised, Double-blind, Controlled Pilot Study
NCT00625742	Terminated	An Exploratory Trial of a Multimodal Treatment Strategy for Cancer Cachexia
NCT02580422	Terminated	Pilot Project for Cardiopulmonary and Functional Evaluation in Patients with Pancreatic Cancer Associated Cachexia

… Supplemental File 1 Continue

Identification Number	Status	Study Title
NCT04001010	Terminated/ Withdrawn	Safety and Efficacy of PPP011-kit for Improving Physical Functioning and for Modulating CachexiaProgression in Patients with Advanced Cancer and Associated Cachexia: A Randomized, Double Blind, Placebo Controlled, Parallel Group Study
NCT01865903	Terminated/ Withdrawn	Nutritional Problems and Changes in Body Composition in Patients with Non-small Cell Lung Cancer; Incidence, Development and Impact on Quality of Life, Adverse Effects and Survival.
NCT00127387	Terminated/ Withdrawn	A Prospective, Randomized Pilot Study of Enbrel VS Placebo in Patients Receiving Radiation Therapy to Combat Fatigue and Cachexia
NCT02650570	Terminated/ Withdrawn	Mitochondrial Respiratory Function in Mammalian Skeletal Muscle: Metabolic Insights into Cancer and Burn Cachexia Through Comparative Physiology of Humans and Marine Mammals

Supplemental File 2 - Summary of search results by terms and status of the clinical trials



Supplemental File 3 - Reasons for withdrawn or anticipated termination before completion of clinical trials

Reason for Termination	Trials	
	n	(%)
Recruitment	10	(43.5)
Institutional Support & Staff Relocation	4	(17.4)
Funding	2	(8.7)
Change of Sponsor	1	(4.3)
Data variation	1	(4.3)
Time	1	(4.3)
Covid-19	1	(4.3)
Not Specified	3	(13.0)

Supplemental File 4 - Phases and status of clinical trials

Status/Phase	Phase 1	Phase 2	Phase 3	Phase 4	No Phase	Other*
Completed With Results	5	12	12	1	19	3
Completed Without Results	6	8	3	1	34	2
Active	4	5	0	0	52	1
Withdrawn	0	6	5	0	11	1
Total	15	31	20	2	116	7

Numbers represent the amount of clinical trials registered on ClinicalTrials.gov in Phase1-4 or No Phase and their status: completed with results, completed without results, active, or withdrawn. *One trial completed with results and two completed without results were in phase 1 and 2. Two trials completed with results, one active, and one withdrawn were in phase 2 and 3.

Supplemental File 5 - Clinical trials registered on ClinicalTrials.gov that used Fearon's definition or any other criteria to diagnose cancer cachexia within each status

Definition used	Completed with Results (n=52)		Completed Without Results (n=54)		Active (n=62)		Withdrawn (n=23)		Total (n=191)	
	n	%	n	%	n	%	n	%	n	%
Fearon	29	(55.8)	9	(16.6)	24	(38.7)	2	(8.7)	64	(33.5)
Other	14	(26.9)	19	(35.2)	8	(12.9)	13	(56.5)	54	(28.3)
Not Speficied	9	(17.3)	26	(48.2)	30	(48.4)	8	(34.8)	73	(38.2)

n represents the amount of clinical trials registered on ClinicalTrials.gov that used Fearon's definition or any other criteria to diagnose cancer cachexia. % refers to the percentage of clinical trials relative the total of clinical trials within each status (completed with results, completed without results, active, or withdrawn). The % in the "Total" column shows the percentage relative to the total of trials included in the study.

Supplemental File 6 - Clinical trials stratified by clinical trial status studying cachexia but classified under other terms different than "cachexia"

Other Terms Used for Trial Classification	Completed with Results (n=52)		Completed Without Results (n=54)		Active (n=62)		Withdrawn (n=23)		Total (n=191)	
	n	%	n	%	n	%	n	%	n	%
Sarcopenia	5	(9.6)	6	(11.1)	16	(25.8)	0	(0.0)	27	(14.1)
Weight loss	9	(17.3)	10	(18.5)	1	(1.6)	3	(13.0)	23	(12.0)
Muscle loss	4	(7.7)	6	(11.1)	9	(14.5)	1	(4.4)	20	(10.5)
Malnutrition	4	(7.7)	3	(5.5)	1	(1.6)	1	(4.4)	9	(4.7)

n represents the number trials classified as sarcopenia, weight loss, muscle loss, or malnutrition studies. Trials are stratified by clinical trial status (completed with results, completed without results, active, or withdrawn).

Supplemental File 7 - Study population of clinical trials registered on ClinicalTrials.gov investigating cancer cachexia

A)

Study Population		Completed Trials with Results (n=52)	Completed Trials Without Results (n=54)	Active Trials (n=62)	Withdrawn Trials (n=23)	Total (n=191)
		n (%)	n (%)	n (%)	n (%)	n (%)
Enrollment	1-50	22 (42.3)	19 (35.2)	18 (29.0)	13 (56.5)	72 (37.7)
	51-100	12 (23.1)	17 (31.5)	18 (29.0)	2 (8.7)	49 (25.7)
	101-500	15 (28.8)	13 (24.1)	22 (35.5)	1 (4.4)	51 (26.7)
	501-1000	2 (3.8)	2 (3.7)	2 (3.2)	0 (0.0)	6 (3.1)
	>1000	1 (1.9)	1 (1.9)	2 (3.2)	0 (0.0)	4 (2.1)
	Not specified	0 (0.0)	2 (3.7)	0 (0.0)	7 (30.4)	9 (4.7)

n represents the number of trials by range of participants enrolled to the clinical trials by clinical trial status (completed with results, completed without results, active, or withdrawn). % refers to the percentage of clinical trials relative the total of clinical trials within each status. The % in the "Total" column shows the percentage relative to the total of trials included in the study.

B)



Dropout percentage (%) in the CTx completed with results that reported "Started" and "Not completed" populations. The dropout percentage is relative to each trial's population (n=28). The "Started" population is labeled on each bar.

Supplemental File 8 - Cancer type and cancer stage of clinical trials registered on ClinicalTrials.gov investigating cancer cachexia

Cancer Type and Stage		Completed Trials with Results (n=52)	Completed Trials Without Results (n=54)	Active Trials (n=62)	Withdrawn Trials (n=23)	Total (n=191)
		n (%)	n (%)	n (%)	n (%)	n (%)
Type of Cancer Studied	**Single cancer type**					
	Lung	8 (15.4)	6 (11.1)	10 (16.1)	5 (21.7)	29 (15.2)
	Pancreatic	3 (5.8)	4 (7.4)	11 (17.7)	4 (17.4)	22 (11.5)
	Gastric/GI*	3 (5.8)	5 (9.3)	8 (12.9)	1 (4.3)	17 (8.9)
	Colorrectal	1 (1.9)	4 (7.4)	5 (8.1)	0 (0.0)	10 (5.2)
	Head & Neck	3 (5.8)	1 (1.9)	1 (1.6)	2 (8.7)	7 (3.7)
	Others	2 (3.8)	4 (7.4)	5 (8.1)	0 (0.0)	11 (5.8)
	Combination of 2					
	Lung + other	5 (9.6)	5 (9.3)	2 (3.2)	2 (8.7)	14 (7.3)
	GI + other	0 (0.0)	2 (3.7)	1 (1.6)	0 (0.0)	3 (1.6)
	Combination of 3					
	Lung + Pancreatic + Colorectal	1 (1.9)	0 (0.0)	2 (3.2)	1 (4.3)	4 (2.1)
	Others	1 (1.9)	2 (3.7)	2 (3.2)	1 (4.3)	6 (3.1)
	Combination of 4 or more	8 (15.4)	6 (11.1)	6 (9.7)	2 (8.7)	22 (11.5)
	Not specified	17 (32.7)	15 (27.8)	9 (14.5)	5 (21.7)	46 (24.1)
Cancer Stage	**Single stage**	0 (0.0)	2 (3.7)	2 (3.2)	2 (8.7)	6 (3.1)
	Mixed					
	Stage I-III	0 (0.0)	0 (0.0)	1 (1.6)	0 (0.0)	1 (0.5)
	Stage II-III	2 (3.8)	0 (0.0)	2 (3.2)	0 (0.0)	4 (2.1)
	Stage I-IV	0 (0.0)	1 (1.9)	1 (1.6)	1 (4.3)	3 (1.6)
	Stage II-IV	1 (1.9)	2 (3.7)	3 (4.8)	1 (4.3)	7 (3.7)
	Stage III-IV	9 (17.3)	5 (9.3)	4 (6.5)	6 (26.1)	24 (12.6)
	Not Specified	40 (76.9)	44 (81.5)	49 (79.0)	13 (56.5)	146 (76.4)

n represents the number of clinical trials that stated 1, 2, 3, or 4 and more cancer types and the cancer stage. % refers to the percentage of clinical trials relative the total of clinical trials within each status. The % in the "Total" column shows the percentage relative to the total of trials included in the study. *GI = gastrointestinal. Due to the uncertainty in some studies that reported gastric or gastrointestinal cancer without further details, gastrointestinal cancer was considered as a singular type of cancer rather than as a collection of conditions that can affect the entire gastrointestinal tract.

Supplemental File 9 - Clinical trials approach and intervention utilized of clinical trials registered on ClinicalTrials.gov investigating cancer cachexia

Approach		Completed with Results (n=52)	Completed Without Results (n=54)	Active (n=62)	Withdrawn (n=23)	Total (n=191)
		n %	n %	n %	n %	n %
Study Type	**Observational**	7 (13.5)	20 (37.0)	20 (32.3)	4 (17.4)	51 (26.7)
	Interventional	45 (86.5)	34 (63.0)	42 (67.7)	19 (82.6)	140 (73.3)
Intervention	**Drug**	28 (53.8)	14 (25.9)	11 (17.7)	11 (47.8)	64 (33.5)
	Dietary Supplement	8 (15.4)	7 (13.0)	7 (11.3)	6 (26.0)	28 (14.7)
	Exercise/Physical Therapy	1 (1.9)	6 (11.1)	8 (12.9)	0 (0.0)	15 (7.9)
	Multimodal	6 (11.5)	3 (5.6)	8 (12.9)	1 (4.4)	18 (9.4)
	Dietary Supplement and Exercise	5 (9.6)	0 (0.0)	2 (3.2)	0 (0.0)	7 (3.7)
	Dietary Supplement and Drug	1 (1.9)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.5)
	Dietary Supplement and Nutrition Counseling	0 (0.0)	1 (1.9)	0 (0.0)	0 (0.0)	1 (0.5)
	Dietary Supplement, Exercise, and Drug	0 (0.0)	0 (0.0)	0 (0.0)	1 (4.4)	1 (0.5)
	Drug and Exercise	0 (0.0)	2 (3.7)	0 (0.0)	0 (0.0)	2 (1.1)
	Nutrition Counseling and Exercise	0 (0.0)	0 (0.0)	4 (6.5)	0 (0.0)	4 (2.1)
	Nutrition Counseling, Exercise, and Phycological	0 (0.0)	0 (0.0)	1 (1.6)	0 (0.0)	1 (0.5)
	Education and Psychological	0 (0.0)	0 (0.0)	1 (1.6)	0 (0.0)	1 (0.5)
	Other	2 (3.8)	4 (7.4)	10 (16.1)	1 (4.4)	17 (8.9)
	None	7 (13.5)	20 (37.0)	18 (29.0)	4 (17.4)	49 (25.7)

n represents the amount of clinical trials registered on ClinicalTrials.gov that utilized and observational or interventional approach for their study. This table also shows the intervention utilized (drug testing, dietary supplement, exercise/physical therapy, a combination of 2 or more interventions (multimodal), others, or none or non-stated intervention. % refers to the percentage of clinical trials relative the total of clinical trials within each status (completed with results, completed without results, active, or withdrawn). The % in the "Total" column shows the percentage relative to the total of trials included in the study.

Supplemental File 10 - Pharmaceutical drugs and dietary supplements evaluated in CTx between 1995-2024.

CTx Identification Number	Treatment	Class
NCT00866970	ALD518	IL-6 inhibitor / Monoclonal antibody
NCT02138422, NCT03207724	Xilonix	Anti-IL-1α monoclonal antibody
NCT01395914, NCT01387282, NCT01387269, NCT03743064, NCT03637816, NCT01505764, NCT04844970, NCT00219817, NCT00267358, NCT00378131	Anamorelin HCl / RC-1291	Ghrelin receptor agonist / Appetite stimulant
NCT00066248, NCT01132547	Cyproheptadine hydrochloride	Antihistamine / Appetite stimulant
NCT00933361	Ghrelin	Peptide hormone (appetite stimulant)
NCT01614990	Macimorelin	Ghrelin receptor agonist
NCT03283488, NCT00004912, NCT00637728, NCT01501396, NCT00066248	Megestrol	Progestin / Appetite stimulant
NCT00625742	Atenolol	β-blocker (antihypertensive)
NCT01238107	MT-102	β-blocker + anabolic agent
NCT00895726	APD209	β-Adrenoceptor agonist
NCT00535015	Betamarc	β-adrenergic agent
NCT04815551, NCT05865535	AV-380	Anti-GDF-15
NCT05546476, NCT04299048, NCT04803305	Ponsegromab / PF-06946860	Anti-GDF15
NCT01433263	BYM338 / Bimagrumab	Anti-ActRII
NCT02359123	Cannabics	Cannabis-based therapy
NCT04585841	Cannabidiol (CBD)	Phytocannabinoid
NCT03245658	THC and CBD Mixture	Phytocannabinoids
NCT04001010	PPP011	Cannabinoid-based
NCT06166134, NCT06137508, NCT05954117, NCT00040885, NCT00060502, NCT01127386	Antineoplastic agents	Chemotherapy / Immunomodulators
NCT04600154	MS-20	Targeted cancer therapy
NCT02416570	Clarithromycin	Antibiotic
NCT00127387, NCT00046904	Enbrel / Etanercept	TNF inhibitor
NCT00040885, NCT00060502	Infliximab	TNF inhibitor
NCT00329615	Insulatard, flexpen	Long-acting insulin
NCT05919147	Pioglitazone	Thiazolidinedione (insulin sensitizer)
NCT03254173, NCT03283488	Mirtazapine / Remeron	Antidepressant / Appetite stimulant
NCT00489593	Olanzapine	Antipsychotic
NCT03263520	Nandrolone Decanoate; Dexamethasone	Anabolic steroid + Corticosteroid
NCT00878995	Testosterone Enanthate	Anabolic androgenic steroid
NCT01355497, NCT01355484, NCT00467844	GTx-024 / Enobosarm	Selective androgen receptor modulator (SARM)
NCT04906746, NCT02072057	Ruxolitinib	JAK1/2 inhibitor

… Supplemental File 10 Continue

CTx Identification Number	Treatment	Class
NCT04034745	Telotristat ethyl	Tryptophan hydroxylase inhibitor
NCT00527319	VT-122	COX-2 inhibitor + PPARγ agonist
NCT05336266	Ketorolac Tromethamine	Non-steroidal anti-inflammatory
NCT00196885	N-acetylcysteine	Antioxidant / Glutathione precursor
NCT00513357, NCT00625742	Melatonin	Hormone / Sleep aid / Antioxidant
NCT04208334, NCT05856500	Curcumin	Anti-inflammatory / Antioxidant
NCT00815685, NCT00031707	Eicosapentaenoic Acid	ω-3 fatty acid / Anti-inflammatory
NCT00094562, NCT04699760, NCT04161794	Fish oil supplement	ω -3 fatty acid / Anti-inflammatory
NCT01596933	BioMega SDA®	ω-3 fatty acid / Anti-inflammatory
NCT03720158, NCT06015971, NCT02779868, NCT00003077	Omega 3	ω-3 fatty acid / Anti-inflammatory
NCT05623852	Fucoidan	Immune-modulatory / Antioxidant
NCT00014248	Adenosine triphosphate	Cellular energy molecule
NCT00081250, NCT05856500	Creatine monohydrate	Ergogenic aid
NCT02561143	Atta	Nutritional supplement
NCT00625742, NCT00053053	Juven	Nutritional supplement
NCT02515032	Nutrifriend Cachexia	Nutritional supplement
NCT03316157	Prosure	Nutritional supplement
NCT04131426	Remune	Nutritional supplement
NCT04643613	Protison cancer nutritional formula (PCNF)	Nutritional supplement
NCT02877966	Amixea	Nutritional supplement
NCT05771207	Protein	Protein supplement
NCT01046383	IMN1207	Cysteine-Rich Non-Denatured Whey Protein Isolate
NCT01694602	3-methylhistidine (D-3MH)	Amino acid derivative
NCT01330823	L-Carnitine	Amino acid derivative
NCT06027242, NCT05023499	glutamine	Amino acid
NCT03253029	Branched Chain Amino Acid	Amino acid
NCT04098237	Pancrelipase	Digestive enzyme
NCT03144128, NCT04864431	Vitamin D	Vitamin
NCT05194397	Nicotinamide Riboside	Vitamin
NCT05264038	OC514	"Anticachexia agent" mechanism of action as of yet undisclosed

Supplemental File 11 – Biomarkers measured in cancer cachexia clinical trials registered on ClinicalTrials.gov

Category	Markers
Inflammation	CRP, TNF-a, TNF-b, IL-1, IL-1B, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-15, IL-1ra, IFN Gamma, neutrophil/lymphocyte ratio, activin A, Myostatin, MCP1, ICAM-1, bFGF, G-CSF, Eotaxin, CCL11, IP10, CXCL10, PDGF, VEGF, RANKL, OPG, DLL1, Periostin, CCL5, CCL4, MIP1b, CCL2, CCL3, IGF1, IGFBP3, GDF11, GDF15, p38, IKK, p65, ERK1/2, JNK, p-selectin.
Metabolism	Blood glucose, Glucose, Proteasome Activity, Serum Albumin, Pre-albumin, Albumin, Total protein, Fibrinogen, Calcium, Sodium, Chloride, Bicarbonate, LDH, Triglycerides, Glycerol, Free fatty acids, Cholesterol, Transferrin, Hb1Ac, Vitamin A, Vitamin E.
Hematology	Hemoglobin, Hematocrit, Erythrocytes, Mean Corpuscular Volume, Leukocytes, Lymphocytes, Platelets, Coagulation test, NK cells, T cells.
Liver/Kidney Function	Bilirubin, Aspartate Aminotransferase, Alkaline Phosphatase, Creatinine, ALT, AST, Urea, Protein.
Urianalysis	Urine Glucose, Ketones, Urine Protein, Urine Hemoglobin, Urobilinogen, Nitrite, Leukocyte Esterase, Hyaline Casts, Urinary 3-methylhistidine.
Homones	Leptin, Ghrelin, Insulin, TSH, LH, FSH, E2, DHEA-S, Testosterone, T4, GLP1, NPY.
Molecular/genetic	EGFR, ALK, ROS1, BRAF, HER2, K-RAS, UBE2B, UBE2D2, MaFbx, MuRF1, Nedd4, Mdm2, 26S proteasome subunits, beclin, LAMP, PARP, K48, K63, NRF2, KEAP1, HSP, ER-stress, Pax3, Pax7, Myf5, M-cadherin, myogenin, desmin, SMAD3.
Microbiome	Stool sample microbiome analysis, Fecal microbiota, Gut permeability markers, Microbial metabolites.
Muscle metabolism/structure	Muscle biopsies, Muscle protein synthesis, ATP concentration in myotubes, Mitochondrial respiration.
Bone metabolism/structure	RANKL, Osteoprotegerin, Vitamin D, Calcium, Phosphate, Vitamin K, vitamin K-PT.
Biopsies	Adipose tissue biopsy, Muscle biopsy, Tumour biopsy, Subcutaneous adipose tissue, Histological analysis.
Others	Total RNA, Reactive oxygen species, Apoptosis markers, Caspase-3, Phosphorylated Akt, Nitrosylated HNE, ATG.

Supplemental File 12 - Outcome measures of cachexia in the clinical trials registered on ClinicalTrials.gov by status

Measures of Cachexia		Completed with Results (n=52)		Completed Without Results (n=54)		Active (n=62)		Withdrawn (n=23)		Total (n=191)	
		n	%	n	%	n	%	n	%	n	%
Outcome Measures	**Body weight**	26	(50.0)	20	(37.0)	24	(38.7)	11	(47.8)	81	(42.4)
	Body composition	34	(65.4)	26	(48.1)	45	(72.6)	14	(60.9)	119	(62.3)
	Muscle mass	8	(15.4)	11	(20.4)	29	(46.8)	1	(4.3)	49	(25.7)
	Lean body mass	19	(36.5)	10	(18.5)	10	(16.1)	6	(26.1)	45	(23.6)
	Fat mass	7	(13.5)	7	(13.0)	7	(11.3)	0	(0.0)	21	(11.0)
	Physical function	31	(59.6)	22	(40.7)	30	(48.4)	13	(56.5)	96	(50.3)
	Muscle function	22	(42.3)	9	(16.7)	15	(24.2)	10	(43.5)	56	(29.3)
	Physical activity levels	8	(15.4)	4	(7.4)	13	(21.0)	1	(4.3)	26	(13.6)
	Fatigue	8	(15.4)	3	(5.6)	2	(3.2)	1	(4.3)	14	(7.3)
	Quality of life (QoL)	23	(44.2)	10	(18.5)	25	(40.3)	13	(56.5)	71	(37.2)
	Nutrition status/appetite	22	(42.3)	10	(18.5)	15	(24.2)	11	(47.8)	58	(30.4)
	Molecular	19	(36.5)	21	(38.9)	38	(61.3)	9	(39.1)	87	(45.5)
	Safety & tolerability	13	(25.0)	11	(20.4)	10	(16.1)	7	(30.4)	41	(21.5)
	Survival	10	(19.2)	11	(20.4)	12	(19.4)	4	(17.4)	37	(19.4)

n represents the number of outcomes stated during the clinical trials (body weight, body composition, physical function, quality of life, nutrition status/appetite, molecular, safety and tolerability, survival, or others). % refers to the percentage of clinical trials relative the total of clinical trials within each status (completed with results, completed without results, active, or withdrawn). The % in the "Total" column shows the percentage relative to the total of trials included in the study.

Supplemental File 13 - Measurement tools used to investigate cachexia

	Measures of Cachexia	Completed with Results (n=52)	Completed Without Results (n=54)	Active (n=62)	Withdrawn (n=23)	Total (n=191)
		n %	n %	n %	n %	n %
Measurement Tools	**Body Composition Assessment**					
	CT	7 (13.5)	7 (13.0)	19 (30.6)	2 (8.7)	35 (18.3)
	BIA	12 (23.1)	8 (14.8)	8 (12.9)	5 (21.7)	33 (17.3)
	DXA	8 (15.4)	3 (5.6)	8 (12.9)	5 (21.7)	24 (12.6)
	MRI	2 (3.8)	2 (3.7)	4 (6.5)	1 (4.3)	9 (4.7)
	Skinfold	4 (7.7)	0 (0.0)	1 (1.6)	3 (13.0)	8 (4.2)
	MUAC	3 (5.8)	1 (1.9)	0 (0.0)	1 (4.3)	5 (2.6)
	PET	0 (0.0)	1 (1.9)	3 (4.8)	0 (0.0)	4 (2.1)
	Waist-Hip ratio	0 (0.0)	1 (1.9)	2 (3.2)	0 (0.0)	3 (1.6)
	Physical Function Assessment					
	Hand Grip Strenght	19 (36.5)	7 (13.0)	15 (24.2)	9 (39.1)	50 (26.2)
	Walk test	5 (9.6)	6 (14.8)	13 (21.0)	1 (4.3)	25 (13.1)
	Sit-to-stand	3 (5.8)	3 (5.6)	9 (14.5)	3 (13.0)	18 (9.4)
	Stair Climb	5 (9.6)	2 (3.7)	3 (4.8)	2 (8.7)	12 (6.3)
	SPPB	0 (0.0)	5 (9.3)	3 (4.8)	0 (0.0)	8 (4.2)
	Accelorometry	3 (5.8)	0 (0.0)	1 (1.6)	0 (0.0)	4 (2.1)
	Symptom and QoL Assessment					
	ECOG	23 (44.2)	12 (22.2)	19 (30.6)	9 (39.1)	63 (33.0)
	EORTC QLQ	12 (23.1)	8 (14.8)	13 (21.0)	7 (30.4)	40 (20.9)
	FAACT	11 (21.2)	7 (13.0)	7 (11.3)	1 (4.3)	26 (13.6)
	Karnofsky scale	5 (9.6)	3 (5.6)	4 (6.5)	5 (21.7)	17 (8.9)
	FACIT-F	4 (7.7)	2 (3.7)	2 (3.2)	0 (0.0)	8 (4.2)
	Nutrition and Appetite Assessment					
	Dietary recall/food diary	4 (7.7)	5 (9.3)	5 (8.1)	4 (17.4)	18 (9.4)
	PG- SGA	2 (3.8)	1 (1.9)	2 (3.2)	2 (8.7)	7 (3.7)
	VAS	4 (7.7)	0 (0.0)	0 (0.0)	2 (8.7)	6 (3.1)
	SNAQ	2 (3.8)	1 (1.9)	1 (1.6)	0 (0.0)	4 (2.1)
	Molecular Assessment					
	Blood sample	17 (32.7)	25 (46.3)	34 (54.8)	9 (39.1)	85 (44.5)
	Muscle biopsy	0 (0.0)	7 (13.0)	11 (17.7)	3 (13.0)	21 (11.0)

CT: Computed Tomography, BIA: Bioelectrical Impedance Analysis, DXA: Dual Energy X-ray Absorptiometry, MRI: Magnetic Resonance Imaging, MUAC: Mid-Upper Arm Circumference, PET: Positron Emission Tomography, SPPB: Short Physical Performance Battery, ECOG: Eastern Cooperative Oncology Group, EORTC QLQ: Research and Treatment of Cancer Quality of Life (QoL) Questionary, FAACT: Functional Assessment of Anorexia/Cachexia Treatment, FACIT-F: Functional Assessment of Chronic Illness Therapy – Fatigue, PG- SGA: Patient-Generated Subjective Global Assessment, VAS: Visual Analog Scale, SNAQ: Simplified Nutritional Appetite Questionnaire.